ES2537591T3 - Nuevos compuestos hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona - Google Patents

Nuevos compuestos hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona Download PDF

Info

Publication number
ES2537591T3
ES2537591T3 ES12721814.7T ES12721814T ES2537591T3 ES 2537591 T3 ES2537591 T3 ES 2537591T3 ES 12721814 T ES12721814 T ES 12721814T ES 2537591 T3 ES2537591 T3 ES 2537591T3
Authority
ES
Spain
Prior art keywords
phenyl
trifluoromethoxy
pyrrolo
substituted
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12721814.7T
Other languages
English (en)
Spanish (es)
Inventor
Aurelia Conte
Daniel Hunziker
Werner Neidhart
Matthias Nettekoven
Tanja Schulz-Gasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2537591T3 publication Critical patent/ES2537591T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
ES12721814.7T 2011-05-17 2012-05-14 Nuevos compuestos hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona Active ES2537591T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166437 2011-05-17
EP11166437 2011-05-17
PCT/EP2012/058852 WO2012156339A1 (en) 2011-05-17 2012-05-14 New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds

Publications (1)

Publication Number Publication Date
ES2537591T3 true ES2537591T3 (es) 2015-06-09

Family

ID=46124329

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12721814.7T Active ES2537591T3 (es) 2011-05-17 2012-05-14 Nuevos compuestos hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona

Country Status (11)

Country Link
US (1) US8501768B2 (OSRAM)
EP (1) EP2709984B1 (OSRAM)
JP (1) JP2014513703A (OSRAM)
KR (1) KR20140042814A (OSRAM)
CN (1) CN103562180B (OSRAM)
BR (1) BR112013028368A2 (OSRAM)
CA (1) CA2832334A1 (OSRAM)
ES (1) ES2537591T3 (OSRAM)
MX (1) MX346980B (OSRAM)
RU (1) RU2013153898A (OSRAM)
WO (1) WO2012156339A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
TW201605791A (zh) 2013-09-26 2016-02-16 美涅莫辛製藥公司 Nr2b之選擇性八氫-環戊二烯并[c]吡咯負向調節劑
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CN107567453A (zh) * 2015-03-13 2018-01-09 艾伯维公司 (吲唑‑4‑基)六氢吡咯并吡咯酮类及使用方法
JP7051846B2 (ja) 2016-11-10 2022-04-11 ケロス セラピューティクス インコーポレイテッド アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
SK12752002A3 (sk) * 2000-03-07 2003-04-01 Aventis Pharma Deutschland Gmbh Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy
CA2436943A1 (en) * 2000-12-01 2003-06-06 Cerep Sa Hydantoin compounds useful as anti-inflammatory agents
CN101115741A (zh) * 2005-02-15 2008-01-30 诺和诺德公司 3,4-二氢-1h-异喹啉-2-羧酸5-氨基吡啶-2-基酯
CN101336243A (zh) * 2005-12-05 2008-12-31 因塞特公司 内酰胺化合物和其使用方法
ES2344616T3 (es) * 2006-04-25 2010-09-01 ELI LILLY & COMPANY Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1.
CA2685543A1 (en) * 2007-04-27 2008-11-13 Sanofi-Aventis 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as scd inhibitors
WO2010108268A1 (en) 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2735411T3 (es) * 2009-10-23 2019-12-18 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6

Also Published As

Publication number Publication date
CA2832334A1 (en) 2012-11-22
EP2709984A1 (en) 2014-03-26
KR20140042814A (ko) 2014-04-07
CN103562180A (zh) 2014-02-05
BR112013028368A2 (pt) 2017-01-24
WO2012156339A1 (en) 2012-11-22
EP2709984B1 (en) 2015-03-18
RU2013153898A (ru) 2015-06-27
HK1191942A1 (zh) 2014-08-08
US8501768B2 (en) 2013-08-06
US20120295934A1 (en) 2012-11-22
CN103562180B (zh) 2016-04-20
MX2013011628A (es) 2013-10-25
MX346980B (es) 2017-04-07
JP2014513703A (ja) 2014-06-05

Similar Documents

Publication Publication Date Title
ES2537591T3 (es) Nuevos compuestos hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona
CN110573499B (zh) αvβ6整合蛋白的抑制剂
EP3638227B1 (en) Spirocyclic indolines as il-17 modulators
JP7264810B2 (ja) アルファvインテグリン阻害剤としてのシクロブタン-およびアゼチジン-含有の単環およびスピロ環式化合物
EP3481828B1 (en) Spiro-fused cyclic ureas as inhibitors of rock
CN107406426B (zh) 作为rock抑制剂的环状脲类
ES2983724T3 (es) Derivados de difluorociclohexilo como moduladores de IL-17
CA3110767A1 (en) Benzimidazolone derivatives, and analogues thereof, as il-17 modulators
JP4932065B2 (ja) βセクレターゼ阻害剤としてのラクタム
SK15702003A3 (sk) Substituované deriváty 1-oxa-2,8-diaza-spiro[4,5]dec-2-énu, spôsob ich výroby, liečivá tieto látky obsahujúce a ich použitie
JP7579249B2 (ja) ヒストンアセチラーゼp300阻害剤及びその用途
CA2210966A1 (en) Bicyclic substituted hexahydrobenz[e]isoindole alpha-1- adrenergic antagonists
WO2012022121A1 (zh) 作为盐皮质激素受体拮抗剂的并环类化合物
US20080200454A1 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
EP1819332B1 (en) Pyrrolopyridine-2-carboxylic acid amides
JP2025525622A (ja) Il-17モジュレーターとしてのイミダゾトリアジン誘導体
WO2012004400A1 (en) Novel spiroheterocyclic compounds as mglu5 antagonists
TW202108147A (zh) 化學化合物
US20130150376A1 (en) Novel Sultam Compounds
CA3209693A1 (en) Substituted pyridine-2,4-dione derivatives
CA2834497A1 (en) New hexahydropyrroloimidazolone compounds
HK1191942B (en) New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
US20220213089A1 (en) Inhibiting cyclic amp-responsive element-binding protein (creb)
HK1179248B (en) Novel spiroheterocyclic compounds as mglu5 antagonists